Clinical Trial Search

Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005

Primary: Stability of Fixation — 0.8; 1.1 degrees

Primary: Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies — 12.43; -2.51…

Primary: Change From Baseline (Expressed As A Ratio) In 24-Hr Serum Cortisol Weighted Mean Following 6 Weeks Of Treatment — 1.04; 1.10 ratio

Primary: Maximum Observed Plasma Concentration (Cmax) of BMS-790052 — 380; 382; 317; 698 nanograms/milliliter (ng/mL)

Primary: Safety — 4 participants

Primary: Percentage of Participants Alive and Without Progressive Disease at Month 6 — 25.6; 30.0 percentage of participants

Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 percentage of participants

Primary: Number of Participants Completing Continuous Four-week Abstinence From Smoking Between the 8-week and 11-week Post Quit Day Visits — 41; 38 participants

Primary: Change From Baseline in Trough Morning Forced Expiratory Volume in 1 Second (FEV1) at Day 85 — 0.231; 0.203 Liter

Primary: Relative Change in Reactive Hyperemia Index (RHI) — 6.65; -1.27 percent change — p=0.292

Primary: Percentage of Participants With Diphtheria and Tetanus Post-vaccination Booster Response Following Vaccination With Either SP306 or DT — 99.7; 98.3; 100; 93.8 Percentage…

Primary: Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale — 4.4; -3.4 Scores on a Scale

Primary: Incidence of Coughing — 10; 6 participants

Primary: Effectiveness at Stopping Distal Pulse — 97; 27; 83; 93 percentage of participants